Psilocybin Composition for Early Stroke Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological agents have not effectively investigated the protective effect of psilocybin in stroke models, particularly in preventing and treating ischemic brain injury.
Innovation Solution
Administering a therapeutically effective amount of psilocybin or its pharmaceutically acceptable salts pre-stroke or early post-stroke, utilizing a pharmaceutical composition that includes psilocybin with carriers and excipients to mitigate neuronal loss and inflammation, and upregulate neurotrophic factors like BDNF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmacological agents are used to treat stroke, then stroke treatment is provided, but protective effects against ischemic brain injury are insufficient
Solution Approach 1:
The patent changes the pharmacological parameter by introducing psilocybin, a serotonin receptor agonist not previously used for stroke treatment, thereby achieving protective effects against ischemic brain injury that conventional agents have not demonstrated
Solution Approach 2:
The patent uses psilocybin as an intermediary substance that mediates the protective effect against ischemic brain injury through serotonin receptor activation, bridging the gap between conventional treatment and effective neuroprotection
2Reliability
If psilocybin is administered pre-stroke or early post-stroke, then neuroprotective effects are achieved, but the therapeutic window is limited
Solution Approach 1:
The patent applies preliminary action by administering psilocybin pre-stroke or in the early post-stroke period, before the full extent of ischemic damage occurs, thereby achieving neuroprotective effects while acknowledging the time-sensitive nature of stroke treatment
3Object-affected harmful factors
If psilocybin is used to reduce brain infarction and inflammation, then neurological deficits are reduced, but safety and regulatory concerns arise
Solution Approach 1:
The patent converts the potential harm of psilocybin's psychoactive effects into benefit by utilizing its serotonin receptor agonist properties to achieve neuroprotection, anti-inflammation, and reduction of brain infarction, thereby transforming a substance with regulatory concerns into a therapeutic agent with demonstrated protective effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Psilocybin demonstrates neuroprotective effects by reducing neurological deficits, brain infarction, and improving locomotor function in stroke models through anti-inflammatory and neurotrophic actions.
Implementation Method 1
Psilocybin is a prodrug and undergoes dephosphorlyation to Psilocin in vivo
Implementation Method 2
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a substituted indolealkylamine and belongs to the group of hallucinogenic tryptamines
Data Source
AI summary
Methods for the prevention and treatment of stroke in a mammal including administering a therapeutically effective amount of psilocybin or a pharmaceutically acceptable salt or solvate thereof, to a mammal in need thereof. Use of a pharmaceutical composition including psilocybin or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients for the prevention and treatment of stroke in a mammal.